Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease is a research paper published in Therapeutic Advances in Gastroenterology (2023). On theSindex it has a DataRank of 0. It has been cited 8 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: F32 DK134043
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: R01 DK 125687
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: R01 DK118154
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: T32 DK 062708
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: T32 DK 094775
FWCI
1.69
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
sj-docx-1-tag-10.1177_17562848221148254 – Supplemental material for Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
sj-docx-1-tag-10.1177_17562848221148254 – Supplemental material for Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease